Evidence map›Paper›PMID 40708199›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2025

Cell-selective telomere damage by thiopurine-based oligonucleotide for diffuse large B cell lymphoma immunotherapy.

Chunsong Yu, Elaine Y Kang, Dongfang Wang, Yong Liang, Piotr Swiderski, Ye Feng, Haiqing Li, Timothy Synold, Stephen Forman, Larry Kwak and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. A sophisticated approach to targeting TERT activity in DLBCL.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Chunsong YuDepartment of Immuno-Oncology, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Elaine Y KangDepartment of Immuno-Oncology, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Dongfang WangDepartment of Immuno-Oncology, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Yong LiangDNA/RNA Synthesis Core Laboratory, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Piotr SwiderskiDNA/RNA Synthesis Core Laboratory, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Ye FengAnalytical Pharmacology Core, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Haiqing LiIntegrative Genomics and Bioinformatics Core, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Timothy SynoldAnalytical Pharmacology Core, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Stephen FormanDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Larry KwakDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA, USA; Toni Stephenson Lymphoma Center, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Marcin KortylewskiDepartment of Immuno-Oncology, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. Electronic address: mkortylewski@coh.org.

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI John Charles Williams · 1985 to 2026
$86.3M
Transplant for Lymphoma:Therapy-Related LeukemiaP50CA107399 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI FORMAN, STEPHEN J, KWAK, LARRY W · 2004 to 2022
$35.5M
NCI NIH HHS P30 CA033572NCI NIH HHS P50 CA107399
6 · The paper itself

Abstract

Telomerase (TERT) is an enzyme involved in maintaining telomere length in diffuse large B cell lymphoma (DLBCL). Previous attempts to target TERT

Indexed as

ImmunotherapyLymphoma, Large B-Cell, DiffuseOligonucleotidesTelomereAnimalsApoptosisCell Line, TumorDisease Models, AnimalHumansMiceTelomeraseXenograft Model Antitumor AssaysOligonucleotidesTelomerase6-thio-deoxyguanosineB cell lymphomacancer immunotherapyDNA damageimmunotherapyinterferonoligonucleotidestingtelomerasetelomere

Identifiers

PMID40708199
PMCPMC12380039

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.